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tively. DISCUSSION : In absence of head-to-head trials, indirect comparisons can 
provide useful insights to clinicians and reimbursement-decision making on relative 
efficacy of treatments. The probabilistic interpretation of Bayesian results suits these 
purposes, allowing probabilistic statements on which treatment is likely to be the 
most effective. Bayesian probabilities and credible intervals have different interpre-
tation than classical p-values and confidence intervals. Bayesian results fit well in 
decision modelling, as resulting posterior distributions can serve as priors in proba-
bilistic cost-effectiveness modelling. Assumptions behind NMA to generate unbi-
ased results were considered valid for IBR vs IDEL+OFA-comparisons, as included 
patient-populations were nearly identical. Estimates versus PC may be conservative, 
given higher relative treatments effect in more severe patients. ConClusions: 
In absence of direct evidence, NMA-results suggest improved PFS and OS for IBR 
compared to IDEL+OFA and to PC in R/R CLL-patients with high certainty, and can 
serve as input in HTA-decision modelling.
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objeCtives: This study aims to investigate the association of the major molecular 
response (MMR) and complete cytogenetic response (CCyR) as surrogate outcomes 
with overall survival (OS) and progression free survival (PFS) in chronic phase of 
chronic myeloid leukemia (CML-CP) patients using evidence from observational or 
experimental study. Methods: We conducted using existing systematic reviews 
and meta-analysis to quantify the association between CCyR and/or MMR at 12 
months and OS and/or PFS. The overall survival rate or progression free survival rate 
according to the responders or non-responders of MMR or CCyR at 12 months after 
the initiation of first-line TKI therapy (imatinib, dasatinib or nilotinib) was extracted 
by two independent reviewers. A weighted average of the OS and PFS at differ-
ent yearly intervals was estimated respectively for both the responders and non-
responders with assumption of no censoring. The analyses were carried out using 
R package “metafor”. Results: Eleven studies provided data on the association 
between CCyR or MMR and OS or PFS after imatinib treatment however there were 
no such studies about dasatinib or nilotinib treatment. Patients who experience 
CCyR following 12 months’ TKI therapy have better long-term (7 –year) OS and PFS 
(OS 97.0% vs 82.5; PFS 97.0% vs 69.6%) than patients who are non-responders at 12 
months. Patients who experience MMR at 12 months’ TKI therapy have better long-
term (5-year) OS and PFS (OS 99.4% vs 93.4%; PFS: 89.9% vs 85.3%). ConClusions: 
This study identified evidence of the association between CCyR and/or MMR and 
survival among the TKI treated CML-CP patients, and this is based entirely on 
imatinib treatment studies. The evidence of dasatinib and nilotinib is limited by 
the amount and quality of data available. Therefore further research is needed 
whether this relationship between the surrogate outcomes and final outcomes are 
equally applicable to dasatinib and nilotinib.
PCN19
COmPArisON Of treAtmeNt durAtiON AmONg tArgeted AgeNts iN 
reNAl Cell CArCiNOmA (rCC)
Feinberg BA1, Bohr M1, Drenning J2, Garofalo DF1, Montgomery J2
1Cardinal Health, Dublin, OH, USA, 2Cardinal Health, Dallas, TX, USA
objeCtives: Conducting comparative effectiveness research among multiple 
classes of treatments may inform optimal treatment based on the real-world 
effectiveness. We conducted a retrospective analysis comparing the duration of 
six leading treatment options in renal cell carcinoma stratified by line of ther-
apy. Methods: Using claims data (MORE2 Registry), patients with renal cell car-
cinoma who started and completed at least one line of treatment during the study 
period (January 2012 to February 2014) were identified by ICD9 code 189.0. Line 
of therapy (LOT) was assigned based on the patient’s available treatment history. 
Analysis was stratified by LOT. Univariate analysis of variance was performed to 
compare mean durations among treatment options, LOT, and therapeutic class. 
Multivariate analysis controlling for demographic and treatment characteristics 
will be presented in the poster. Results: Patients received 1240 complete lines 
of therapy. Mean duration of treatment by line of therapy was as follows: 1st LOT: 
4.0 mo (n= 599); 2nd LOT: 3.2 mo (n= 357); 3rd LOT 3.1 mo (n= 284). There was sta-
tistically significant difference in mean duration of therapy between the groups of 
patients by second line regimen (p= 0.003). Within the second line patient group 
the tyrosine kinase inhibitor (TKI) treated patients had greater duration compared 
to the mammalian target of rapamycin (mTOR) treated patients (3.5 mo vs 2.6 
mo, p-value= 0.006). However no difference in duration was observed among first 
(p= 0.7239) and third line regimens (p= .0.6476). ConClusions: In this study there 
was statistically significant difference in duration among leading systemic agents 
used for second-line treatment of RCC where patients were shown to remain on 
TKI treatment longer than mTOR treatment. Future research should determine if 
toxicity and costs influence duration in this therapeutic area.
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objeCtives: Understanding prescriber perceptions of efficacy and tolerability 
among available RCC treatments in a real-world population may inform current 
areas of unmet need and provide context for the adoption of new therapeutics. We 
conducted a retrospective analysis evaluating the drug utilization patterns and 
duration of tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin 
(mTOR) inhibitors in patients with newly diagnosed and relapsed RCC. Methods: 
Using claims data (MORE2 Registry), patients with RCC who completed at least one 
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objeCtives: To evaluate the patterns of metachronous metastases in patients with 
breast cancer. Methods: Patients diagnosed with non-metastatic (M0) breast cancer 
at initial diagnosis between 2006-2008 were selected from the Eindhoven Cancer 
Registry, which is a population-based registry and records data on newly diagnosed 
cancer patients. By means of active follow-up, additional data on date of diagnosis 
and localization of metachronous metastases were collected directly from the patient 
files. Anatomical sites of metastasis were registered according to the International 
Classification of Diseases for Oncology (ICD-0). Proportions of metachronous metas-
tases between tumour and treatment characteristics were compared using the Chi2 
test. A p-value < 0.05 was considered significant. Results: There were 1,382 patients 
diagnosed with M0 breast cancer with a mean (±SD) age of 60.3 (±13.8) years. Of those, 
116 patients (8%) developed metachronous metastases during a median (±SD) follow-
up of 4.1 (±1.1) years. The mean (±SD) age at the time of diagnosis of metachronous 
metastases was 61.7 (±14.3) years. Diagnosis of metachronous metastases was con-
firmed by imaging in 76 patients (66%), in 39 patients (34%) by histopathology and 1 
patient (1%) based on clinical symptoms. The most frequent metastatic sites affected 
were bone (29%) and liver (17%). Breast cancer patients who developed metachro-
nous metastases were significantly more often diagnosed with a hormone recep-
tor positive and a HER2-negative tumor, had a poor tumor grade, had a tumor size 
greater than 2.1 cm, and more often received chemotherapy at initial breast cancer 
diagnosis. ConClusions: Of the initially M0 breast cancer patients, 8% developed 
metachronous metastases, of which one-third developed bone metastasis. The risk 
of developing metachronous metastases varies among different characteristics at 
initial breast cancer diagnosis. Identifying the patterns of metachronous metasta-
ses and characteristics increasing the risk for developing metachronous metastases 
contributes to tailored follow-up and adequate initial M0 breast cancer treatment.
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objeCtives: Elderly patients with newly diagnosed multiple myeloma (MM) 
are usually not considered for stem cell transplantation. Treatment alternatives 
include multidrug regimens combining prednisone (P)/dexamethasone (D), tha-
lidomide (T), bortezomib (V), cyclophosphamide (C), and melphalan (M). Head-to-
head comparisons between the different treatments are lacking. We compared 
the effectiveness of different first-line treatment strategies for patients with 
MM (age > 65 years) in terms of progression-free survival (PFS) and overall sur-
vival (OS). Methods: We performed a systematic literature search in MEDLINE, 
EMBASE, Cochrane Library and CRD databases. The primary search yielded 2,673 
citations. Ten randomized controlled trials (RCT), enrolling a total of 3,782 patients, 
were included in our meta-analysis and indirect treatment comparisons. We calcu-
lated pooled hazard ratios (HR) with 95% confidence intervals (95%CI). Results: 
Meta-analysis of six RCTs comparing MPT vs. MP showed a statistically significant 
benefit of MPT in PFS (HR 0.75, 95%CI 0.64-0.88) but no statistically significant dif-
ference in OS (HR 0.90, 95%CI 0.75-1.08). The indirect comparison of MPT vs. MPV 
showed a benefit in PFS for MPV (HR 1.41, 95%CI 1.04-1.90) but no OS difference 
(HR 1.29, 95%CI 0.98-1.70) using MP regimen as the common comparator. There 
was no difference between MPT vs. CTD, indirectly analyzed with MP as common 
comparator (PFS: HR 0.91, 95%CI 0.73-1.14; OS: HR 1.01, 95%CI 0.78-1.32). Indirect 
comparison was also possible for VMPT-VT vs. VTD, both compared to MPV in 
the original RCTs. VMPT-VT showed a statistically significant benefit in PFS (HR 
0.48, 95%CI 0.33-0.71) but no difference in OS (HR 1.04, 95%CI 0.69-1.59) compared 
to VTD. ConClusions: While some regimens showed improved PFS, there was 
no evidence for a benefit in OS comparing the different treatment strategies. 
Combining all treatment strategies based on published data by using a network 
meta-analysis may help to identify the optimal treatment option.
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objeCtives: To assess the relative efficacy of ibrutinib (IBR), a first-in-class BTK- 
inhibitor, versus Idelalisib+ofatumumab (IDEL+OFA) and physician’s choice in 
relapsed/refractory (R/R) CLL-patients using Bayesian Network Meta-Analysis 
(NMA). Methods: Three RCTs in R/R CLL-patients were identified with OFA as 
common treatment arm. IBR (Byrd, 2014) and IDEL+OFA (Jones, 2015) showed 
improved investigator-assessed PFS (HR= 0.13 and 0.27, respectively) and OS 
(HR= 0.39 and 0.74, respectively) versus ofatumumab in R/R CLL-patients. Osterberg 
(2014) compared PFS (INV) (HR= 0.56) and OS (HR= 0.72) for OFA to physician’s 
choice (PC), a mix of well-established CLL-treatments, in more severe patients. A 
Bayesian NMA was conducted in line with NICE guidelines, using a fixed-effect 
model with non-informative priors. Posterior distributions for the HR were sum-
marized by median values and 95% credible intervals. Results: HR for PFS (INV) 
comparing IBR vs IDEL+OFA and PC were 0.49 ([0.28;0.87],P(HR< 1)= 99.2%) and 0.07 
([0.04;0.13],P(HR< 1)= 100%), respectively. HR for OS comparing IBR vs IDEL+OFA and 
PC were 0.52 ([0.24;1.14],P(HR< 1)= 94.7%) and 0.28 ([0.13;0.80],P(HR< 1)= 100%), respec-
